Friday
11.15.2019
7:46 AM
Login form
Search
Calendar
Entries archive

My site

Main » 2017 » August » 28

LACHEN, Switzerland-Thursday, August 24th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously untreated patients (PUPs), on August 16th 2017 as an Early View article in the internationally renowned medical journal Haemophilia.

The NuProtect study was initiated in March 2013 to investigate the immunogenicity, efficacy and safety of Nuwiq® in PUPs with severe haemophilia A, who are at the greatest risk of developing inhibitors. The ongoing study has enrolled 110 PUPs of any age or ethnicity who will receive Nuwiq® for up to 100 exposure days (EDs), making it one of the largest studies with a single FVIII product. Patients who previously received any FVIII concentrates or blood products containing FVIII are excluded from the study.

The recently published article describes interim results ... Read more »

Views: 94 | Added by: uaeonlinenews | Date: 08.28.2017

 ● RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy

● Both Pradaxa® doses tested in RE-DUAL PCI™ have been approved for stroke prevention in atrial fibrillation

● Data were presented as a late-breaker at the ESC Congress 20171 and published in the New England Journal of Medicine2

 

INGELHEIM, Germany-Sunday, August 27th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) and stent placement: results showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with Pradaxa® when compared to triple therapy with warfarin.1,2 The risk for the primary safety endpo ... Read more »

Views: 66 | Added by: africa-live | Date: 08.28.2017 | Comments (0)

● Move underscores belief in the Egyptian market 

● Plays to boost UAE-Egyptian mutual economic and trade interests and relations

● Intended to help stimulate the flow of foreign investments into Egypt

       

Dubai, United Arab Emirates-Monday, August 28th 2017 [ AETOS Wire ]
SHUAA Capital, the United Arab Emirates-based integrated financial services firm, announced that it has formally begun discussions with Egyptian regulators for reintroducing its securities business into the Egyptian market.
As a stepping stone, SHUAA Capital’s Board of Directors has set a clear mandate targeting the Egyptian market for the expansion of the firm’s brokerage services under its broader Capital Markets offering. The decision to restart brokerage operations in Egypt, which was voluntarily suspended previously as the region recovered from the 2008 global recession which impacted trading volumes, is a key component of th ... Read more »

Views: 68 | Added by: uaeonlinenews | Date: 08.28.2017 | Comments (0)

 

INGELHEIM, Germany & SYDNEY-Thursday, August 24th 2017 [ AETOS Wire ]

    Boehringer Ingelheim commences Phase II program of investigational drug candidate BI 1467335 acquired from Pharmaxis with a 12 week Phase IIa proof of clinical principle study in non-alcoholic steatohepatitis (NASH)
    New study underscores Boehringer Ingelheim’s aspiration to deliver more first in class medicines with breakthrough potential for patients with cardio metabolic diseases
    Pharmaxis to receive €18 million milestone payment in a significant further endorsement of the company’s ability to generate value from its early stage pipeline.

(BUSINESS WIRE) -- Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmax ... Read more »

Views: 67 | Added by: africa-live | Date: 08.28.2017

Mopria Contributes Technology in Android 8.0 Oreo’s Default Print Service Providing Effortless Mobile Printing

SAN RAMON, Calif.-Saturday, August 26th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- The Mopria® Alliance, a global non-profit membership organization chartered to drive industry-wide standards and solutions for mobile printing, today announced it provided core printing technology to deliver intuitive mobile printing in the new Android 8.0 Oreo™ operating system. This contribution is the result of ongoing collaboration with the Google Android team via the Android Open Source Project and the Mopria Alliance.
Android 8.0 Oreo’s new Default Print Service features core technology from the Mopria Print Service, immediately delivering mobile printing convenience in the Operating System. With Mopria technology at the core of the Android 8.0 Oreo Default Print Service, users no longer need to download a mobile printing service and printer discover ... Read more »

Views: 78 | Added by: uaeonlinenews | Date: 08.28.2017 | Comments (0)